Abstract. Recent studies of a relatively rare hereditary cancer syndrome, von Hippel-Lindau (VHL) disease, have shed new light on the molecular pathogenesis of kidney cancer and, perhaps more important, on how mammalian cells sense and respond to changes in oxygen availability. This knowledge is already translating into new therapeutic targets for kidney cancer as well as for multiple conditions, such as myocardial infarction and stroke, in which ischemia plays a pathogenic role. This review summarizes the current knowledge of the molecular pathogenesis of von Hippel-Lindau disease and the role of the VHL gene product (pVHL) in kidney cancer and the mammalian oxygen sensing pathway.

von Hippel-Lindau Disease

Approximately 100 yr ago, the British surgeon Treacher Collins described two siblings with retinal blood vessel tumors (1). Shortly thereafter, the German ophthalmologist Eugen von Hippel also described the familial occurrence of such lesions (2). It was the Swedish neuropathologist Arvid Lindau who appreciated that these familial retinal lesions, which are frequently referred to in the literature as angiomas or hemangiomas, were a marker for a systemic disorder (now called von Hippel-Lindau [VHL] disease) that also involved blood vessel tumors, called hemangioblastomas, of the central nervous system (especially the cerebellum and spinal cord) (3). It has been suggested that both the retinal lesions and central nervous system lesions be called hemangioblastomas because they are histopathologically (and probably pathophysiologically) very similar (4). Some patients with VHL disease also develop multiple visceral cysts, especially in the kidneys and pancreas. The renal cysts that develop in VHL disease are precursor lesions that can give rise, over time, to clear cell renal carcinomas (Figure 1). Indeed, hemangioblastomas and clear cell renal cell carcinomas are the two leading causes of death in this patient population (5). Other tumors linked to VHL disease include pheochromocytomas, pancreatic islet cell tumors, endolymphatic sac tumors, and papillary cystadenomas of the epididymis (males) or broad ligament (females). Although highly variable, tumors typically develop in patients with VHL disease in the second, third, and fourth decades of life.

As is true for most hereditary cancer syndromes, VHL disease is linked to inactivation of a tumor suppressor gene (in this case, the VHL gene, which resides on chromosome 3p25) (6). Typically, patients with VHL disease have inherited an inactive VHL allele from an affected parent. In other words, patients with VHL disease are VHL+/− heterozygotes. Some VHL patients without a positive family history have, upon further investigation, been found to have a parent who is mosaic for a VHL mutation (presumably as the result of a de novo mutation during early development) (7,8). Tumor development in VHL disease is linked to inactivation or loss of the remaining wild-type VHL allele in a susceptible cell, which leads to loss of the VHL gene product pVHL. This event can be documented in very early, premalignant, renal lesions (including cysts) in patients with VHL disease (9–11) (Figure 1). It is presumed that mutations that affect one or more other genes is required for conversion of these premalignant renal lesions to frank renal cell carcinomas. More than 30 yr ago, Knudson (12) and Comings (13) both predicted that the genes responsible for hereditary forms of cancer might also play critical roles in their nonhereditary counterparts. Indeed, the VHL gene is frequently inactivated, whether as a result of mutation or hypermethylation, in nonhereditary clear cell renal carcinomas and hemangioblastomas (14). In these settings, VHL gene alterations are not inherited but occur somatically.

The VHL gene contains three exons and encodes an approximately 4.5-kb mRNA that is ubiquitously expressed (15–17). In particular, VHL mRNA expression is not restricted to those tissues that give rise to tumors after VHL inactivation. Alternative splicing gives rise to a second transcript that is missing exon 2. Some tumors exclusively produce this second mRNA isoform, suggesting that its protein product is at least partially defective with respect to tumor suppressor activity (18). The VHL gene is conserved in worms, flies, and rodents (19–23). Heterozygous VHL inactivation in the mouse is embryonic lethal (24,25). VHL+/− mice develop blood vessel tumors of the liver that seem, as in the case of human VHL disease, to be linked to loss of the remaining wild-type VHL allele (25). Why
humans and mice develop tumors at different sites after VHL inactivation is not yet clear. A similar conundrum exists, however, for many other hereditary cancer genes.

**VHL Protein**

The VHL mRNA encodes a protein that contains 213 amino acid residues and migrates with an apparent molecular weight of 24 to 30 kD in SDS-polyacrylamide gels (26). A second protein isoform is produced as a result of internal translation of 24 to 30 kD in SDS-polyacrylamide gels (26). A second acid residues and migrates with an apparent molecular weight gives rise to renal cysts. Conversion of the preneoplastic renal cysts to clear cell renal carcinomas is presumed to involve additional genetic changes at other loci.

Patients with VHL disease are VHL heterozygotes. Inactivation of the remaining wild-type VHL allele in renal tubular epithelial cells gives rise to renal cysts. Conversion of the preneoplastic renal cysts to clear cell renal carcinomas is presumed to involve additional genetic changes at other loci.

The VHL protein is a tumor suppressor that is involved in the regulation of the hypoxia-inducible factor (HIF) pathway. HIF is a transcription factor that is activated under conditions of low oxygen, leading to the upregulation of genes that are involved in angiogenesis and cellular proliferation.

The VHL protein forms a multiprotein complex with elongin B, elongin C, Cul2, and Rbx1 that polyubiquitinylates and hence targets for proteasomal degradation, hypoxia-inducible factor α (HIFα) subunits when oxygen is present. In the absence of oxygen, HIFα subunits accumulate and activate hypoxia-inducible genes.

Tumor formation by pVHL-defective renal carcinoma cells is suppressed after restoration of wild-type pVHL function (26,29,42,43). Thus, pVHL is a tumor suppressor protein based on both genetic and functional criteria. pVHL can also suppress pVHL-defective tumor cell proliferation in vitro under specific experimental conditions such as growth in low serum or as three-dimensional spheroids (44–47). In some of these settings, inhibition of cellular proliferation is accompanied by decreased invasiveness/motility (48) and enhanced differentiation (44,45).

The primary sequence of pVHL does not closely resemble other known proteins and does not contain any obvious structural motifs that might provide clues to its biochemical functions. It is now clear, however, that pVHL forms stable complexes in mammalian cells with other proteins, including elongin B, elongin C, Cul2, and Rbx (also called Roc1 and Hrt1; Figure 2) (21,42,49–54). Importantly, Elledge et al. (55) noted that elongin C and Cul2 resemble two yeast proteins called Skp1 and Cdc53, which were known to regulate protein turnover. In particular, many proteins that undergo regulated destruction are first covalently modified by the attachment of a polyubiquitin tail, which serves as a signal for degradation by a multiprotein complex called the proteasome. Substrate-specific polyubiquitylation involves the sequential action of the E1 ubiquitin activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase. One subfamily of E3 ubiquitin ligases in yeast is made up of Skp1 and Cdc53 bound to one of many F-box proteins (so-named because of a short, collinear, motif first identified in cyclin F) (56,57). In such SCF (Skp1/Cdc53/F-box) complexes, the F-box protein represents the substrate specificity determinant. Analogous complexes exist in mammalian cells, with the function of Cdc53 performed by a member of the Cullin family. The pVHL complex architecturally resembles an SCF complex, with pVHL assuming the role of the F-box protein, and displays ubiquitin ligase activity in vitro (58,59).

The search of substrates of the pVHL ubiquitin ligase complex was aided tremendously by the recognition that pVHL-defective tumors such as hemangioblastomas and renal cell carcinomas are highly vascular and frequently overproduce angiogenic peptides such as vascular endothelial growth factor (VEGF) (60–66). Moreover, hemangioblastomas, renal cell carcinomas, and pheochromocytomas occasionally cause paraneoplastic erythrocytosis as a result of ectopic erythropoietin production (67). Both VEGF and erythropoietin mRNA are induced by inadequate oxygenation and hence referred to as hypoxia-inducible genes (68,69). Earlier studies showed that the production of hypoxia-inducible mRNA is uncoupled from changes in ambient oxygen in pVHL-defective tumor cell lines and that this defect can be corrected by restoration of wild-type pVHL function (43,70–72).
pVHL-Hypoxia–Inducible Factor Connection

Many hypoxia-inducible mRNA are under the control of a heterodimeric transcription factor called hypoxia-inducible factor (HIF), which consists of an α subunit (HIF1α, HIF2α, or HIF3α) and a stable β subunit (HIF1β or ARNT) (68,69). Earlier studies showed that HIFα subunits are normally polyubiquitylated and degraded under well-oxygenated conditions. In a landmark paper, Maxwell et al. (73) showed that pVHL-defective cells fail to degrade HIFα subunits under well-oxygenated (normoxic) conditions and that pVHL and HIF can physically associate. Subsequently, several groups showed that HIFα subunits are polyubiquitylated by the pVHL complex under normoxic conditions (33,74–76) (Figure 2). Importantly, pVHL contains two subdomains, called α and β, that are frequently mutated in VHL Disease (78). The former represents the elongin C binding domain, whereas the latter domain is the HIF binding region.

The accumulation of HIFα subunits under hypoxic conditions reflects that the interaction of pVHL with HIFα is oxygen dependent. In particular, HIFα is hydroxylated on one of two conserved prolyl residues by members of the Egg Laying Defective Nine (EGLN) family (also called the PHD family or HPH family) in the presence of oxygen (22,79–83) (Figure 3). Hydroxylation serves as a signal for recruitment of pVHL. This reaction is inherently oxygen dependent because the oxygen atom of the hydroxyl group is derived from molecular oxygen (Figure 3). Moreover, the EGLN prolyl hydroxylases require iron and 2-oxoglutarate as co-factors. The former explains the hypoxia mimetic effects of iron chelators and antagonists. The crystal structure of pVHL bound to HIF reveals that selective binding to hydroxylated HIF is the result of critical hydrogen bonds between the prolyl hydroxyl group and two hydrophilic pVHL residues within the otherwise hydrophobic pVHL β domain (84,85).

Several lines of evidence suggest that HIF is a/the critical downstream target of pVHL with respect to tumor formation. First, pVHL mutants associated with hemangioblastoma and renal cell carcinoma have, when tested, been defective with respect to HIF polyubiquitylation (74–76,86,87). Second, pVHL tumor suppressor activity can be neutralized by peptides that bind to the pVHL β domain (88). Both of these observations suggest that HIF, or perhaps some other substrate recognized by the β domain, is an important pVHL target. The importance of HIF per se with respect to renal carcinogenesis is underscored by the finding that a HIF1α variant that escapes recognition by pVHL can override pVHL’s tumor suppressor activity in vitro (but not in vivo) (88), whereas a similar HIF2α variant can override pVHL’s tumor suppressor activity in vivo (89). Thus, in the context of renal cell carcinoma, inhibition of HIF is necessary for tumor suppression by pVHL.

Emerging genotype-phenotype correlations in VHL disease strongly suggest that pVHL has functions unrelated to HIF. VHL disease can be subdivided into type 1 (low risk of pheochromocytoma) and type 2 (high risk of pheochromocytoma) (90). Type 2 is subdivided into type 2A (low risk of renal cell carcinoma), type 2B (high risk of renal cell carcinoma), and type 2C (pheochromocytoma only). Type 2 disease is almost invariably associated with VHL missense mutations, suggesting that pheochromocytoma reflects a VHL "gain of function" or that complete loss of pVHL function is incompatible with pheochromocytoma development. When tested, type 2C mutants retain the ability to regulate HIF, in contrast to mutants associated with types 1, 2A, and 2B disease (86,87). Thus, no biochemical gain of function or loss of function has been revealed so far for type 2C mutants. Types 2A and 2B mutants are comparably defective with respect to HIF regulation and yet confer different risks for renal cell carcinoma. One recent report suggested that type 2A mutants, in contrast to 2B mutants, are defective with respect to associating with and stabilizing microtubules (32). Finally, one form of familial polycythemia, called Chuvash polycythemia, was recently linked to a homozygous, hypomorphic, VHL mutation (R200W), which encodes a pVHL mutant that is quantitatively defective with respect to HIF regulation (91). It is interesting that these families do not seem to be at markedly increased risk for tumor formation. Perhaps in keeping with this observation, forced activation of HIF target genes in animal models has not given rise to tumors in the tissues examined to date (92–94). Collectively, these considerations point to pVHL’s having multiple functions, with site-specific tumor risk determined by.

![Figure 3. Oxygen-dependent pVHL binding.](Image)

(A) In the presence of oxygen, HIFα subunits are hydroxylated on one of two conserved prolyl residues. pVHL binds exclusively to hydroxylated HIFα. (B) Hydroxylation of HIFα is carried out by members of the Egg Laying Defective Nine (EGLN) family.
the degrees to which these various functions are quantitatively or qualitatively altered.

**pVHL Targets Other than HIF**

Indeed, a number of functions have been ascribed to pVHL, although in some cases, these functions may ultimately be linked to HIF dysregulation. pVHL has been reported to interact with fibronectin and clearly plays a role in regulation of extracellular matrix assembly and turnover (36, 44, 45, 48). How and to what degree these two findings are linked are still unclear. In addition to affecting fibronectin matrix assembly, pVHL regulates a variety of genes, such as TGF-β, tissue inhibitors of metalloproteinase, and matrix metalloproteinases, that affect matrix turnover and may also affect certain integrins (48, 95, 96).

A number of studies have indicated that pVHL can interact with certain atypical PKC members (97–102). It has been suggested that pVHL directly inhibits PKC activity or acts as a PKC ubiquitin ligase. pVHL also inhibits cyclin D1, although there is no evidence that this involves a direct interaction between pVHL and cyclin D1 (103, 104). Moreover, the effect of pVHL on the cell cycle and cell-cycle regulators might be confounded because some HIF targets, such as TGF-α, are potent renal epithelial mitogens (105–108). Other potential direct targets of pVHL include transcription factor SP1 (109, 110), the large subunit of RNA polymerase II (111), two deubiquitinating enzymes called VDU1 and VDU2 (112, 113), and the RNA-binding protein hnRNP A2 (114). Most of these other pVHL interactors await independent verification.

**Implications for Therapy**

As described above, inactivation of pVHL is an early, causal event in a significant percentage of clear cell renal carcinomas, and preclinical studies indicate that restoring pVHL function in pVHL-defective renal carcinoma cells is sufficient to suppress tumorigenesis. Inhibition of HIF target genes is necessary for tumor suppression by pVHL. Whether it is likewise sufficient is not yet known, although inhibition of HIF in most but not all cancer models has been sufficient to suppress tumor growth. Thus, there is a strong rationale for developing therapies directed against HIF or its downstream targets in renal carcinoma. Unfortunately, sequence-specific DNA-binding transcription factors such as HIF have not yet proved to be highly tractable drug targets. Fortunately, however, a number of HIF-responsive genes implicated in tumorigenesis encode growth factors that might (along with their receptors) be amenable to pharmacologic agents (Figure 4). These include paracrine-acting angiogenic factors such as the VEGF and PDGF, which are thought to stimulate endothelial cells and supporting pericytes, respectively, as well as autocrine growth factors such as TGF-α. These three growth factors bind to membrane-bound receptors that become active as tyrosine kinases upon ligand binding. Treatment with a VEGF neutralizing antibody led to delayed disease progression in a cohort of patients with metastatic renal carcinoma in a randomized phase II trial and is now being tested in phase III (115). A number of drugs that inhibit the tyrosine kinase activity of the VEGF receptor KDR and the PDGF receptor, which are similar proteins because they are phylogenetically related, are currently being tested in human kidney cancer patients. Examples include PTK787 and SU11248 (116–119). In addition, recent studies indicate that the mTOR inhibitor rapamycin and histone deacetylase inhibitors such as trichostatin A also lead to downregulation of VEGF in tumor cell lines and might be tested in this setting as well (120–122). In theory, treatments aimed at VEGF and/or PDGF might be combined with agents such as Iressa that inhibit EGFR (96, 123), which is the receptor for TGF-α. Of note, TGF-α was sufficient to cause renal cysts in one mouse model and thus might provide a link between pVHL inactivation and premalignant cyst formation (124). EGFR inhibitors have been effective in some renal cyst models (125). Also, there is evidence for molecular cross-talk between EGFR signaling and HIF (126). Therefore, drugs that inhibit EGFR might be additive or synergistic with drugs that inhibit other HIF targets.

It is interesting that another HIF target, CAIX, encodes a renal carcinoma antigen previously called G250 (10, 127, 128). Antibodies against G250 might be used to localize tumors and, in time, as therapeutics. Gene expression profiling has uncovered a wealth of additional genes that are differentially expressed by cells that do or do not contain wild-type pVHL, including genes encoding secreted or membrane-bound proteins (104, 129–131). Thus, loss of pVHL and consequent overproduction of HIF target genes might provide a foundation for new immunotherapeutic as well as chemotherapeutic approaches to kidney cancer.

HIF is conserved among metazoans and presumably evolved to enhance the survival of cells exposed to acute or chronic hypoxia (68, 69). HIF induces changes in glucose uptake and

**Figure 4.** Possible kidney cancer drug targets. Inactivation of pVHL leads to overproduction of HIF target genes. Some of these genes encode growth factors, such as vascular endothelial growth factor, PDGF B, and TGF-α, that bind to specific receptors. Signal transduction by these receptors is linked to their ability to serve as tyrosine kinases and can be blocked with drugs currently being tested in humans.
metabolism to allow for continued ATP generation in a hypoxic environment, changes in carbonic anhydrase secretion to compensate for increased lactic acid production resulting form anaerobic glycolysis, and changes in red blood cell production and angiogenesis to enhance oxygen delivery. In theory, a HIF agonist might therefore be beneficial in diseases, such as myocardial infarction and stroke, that are characterized by acute or chronic ischemia (Figure 5). EGLN belongs to a superfamily of iron and 2-oxoglutarate–dependent dioxygenases (132–134). Small molecule EGLN inhibitors that act as iron or 2-oxoglutarate antagonists lead to HIF stabilization and activation of HIF target genes (22,80,81). Of note, a single administration of one such compound (FG-0041) was efficacious in preserving myocardial function in a rat model of myocardial infarction (80,135). Open questions are whether the salutary effects of FG-0041 in this model were truly related to HIF and whether chronic administration of a HIF agonist would be sufficient to produce pathologic changes in the tissues, such as the eye, brain, and kidney, that are affected in VHL disease.

Conclusion
Inactivation of the VHL tumor suppressor gene is an early, causal event in the development of clear cell renal cell carcinomas and hemangioblastomas. Its protein product, pVHL, is part of an E3 ubiquitin ligase complex that targets HIFα subunits for destruction in the presence of oxygen. Accordingly, pVHL-defective tumor cells overproduce a variety of HIF target genes, which have been implicated in metabolism, mitogenesis, and angiogenesis. The products of some of these genes might be suitable targets for pharmacologic or immunologic approaches to kidney cancer. Notably, inhibition of HIF is necessary for renal carcinoma suppression by pVHL in xenograft models. The interaction of pVHL with HIF is governed by prolyl hydroxylation of one of two conserved prolyl residues within the HIFα subunits. This reaction is carried out by members of the EGLN family and is inherently oxygen dependent. Acute inhibition of EGLN might theoretically be useful in the treatment of diseases characterized by inadequate oxygen delivery. It is likely that HIF-independent functions, in a tissue-specific manner, also contribute to tumor development after pVHL inactivation. Further elucidation of these functions should lead to enhanced understanding of renal carcinogenesis and should also speak to the advisability of pharmacologically manipulating HIF activity in humans.

References
1. Collins ET: Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalm Soc UK 14: 141–149, 1894

![EGLN Antagonists](image-url)

Figure 5. EGLN Antagonists. In theory, drugs that blocked EGLN activity would lead to activation of HIF target genes, which might be beneficial in diseases characterized by inadequate tissue oxygenation.
33. Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298–4309, 2000


destruction by proline hydroxylation: Implications for O2 sensit.
80. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V,
2002
Kriegsheim A, Hebestreit H, Mukherji M, Schofield C, Maxwell
P, Pugh C, Ratcliffe P: Targeting of HIF-alpha to the von 
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl 
82. Yu F, White S, Zhao Q, Lee F: HIF-1α binding to VHL is 
regulated by stimulus-sensitive proline hydroxylation. Proc Natl 
83. Yu F, White S, Zhao Q, Lee F: Dynamic, site-specific interaction 
of hypoxia-inducible factor-1α with the von Hippel-Lindau tum-
84. Min JH, Yang H, Ivan M, Gertzler F, Kaelin WG Jr, Pavletich NP:
85. Hou WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh
CW, Maxwell PH, Ratcliffe PJ, Stuart DJ, Jones EY: Structural 
basis for the recognition of hydroxyproline in HIF-1α by pVHL. 
Nature 417: 975–978, 2002
86. Clifford S, Cockman M, Smallwood A, Mole D, Woodward E, 
Maxwell P, Ratcliffe P, Maher E: Contrasting effects on HIF-1α 
regulation by disease-causing pVHL mutations correlate with 
patterns of tumourigenesis in von Hippel-Lindau disease. Hum 
Hippel-Lindau protein mutants linked to type 2C VHL disease 
preserve the ability to downregulate HIF. Hum Mol Genet 10:1019–1027, 2001
88. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, 
Klausner RD: The contribution of VHL substrate binding and 
HFI1-alpha to the phenotype of VHL loss in renal cell carci-
89. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG: 
Inhibition of HIF is necessary for tumor suppression by the von 
90. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, 
Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, 
Brauch H, Glavac D, Neumann HPH, Tisherman S, Mulvihill JJ, 
Gross D, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, 
91. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu 
E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stock-
ton DW, Semenza GL, Prchal JT: Disruption of oxygen ho-
92. Elson D, Thurston G, Huang L, Ginzinger D, McDonald D, 
Johnson R, Arbeit J: Induction of hypervascularity without leak-
age or inflammation in transgenic mice overexpressing hypoxia-
M, Akita G, Gregory R, Isner J: Angiogenesis is induced in a 
rabbit model of hindlimb ischemia by naked DNA encoding an 
HIF-1alpha/VP16 hybrid transcription factor. Circulation 102: 
2255–2261, 2000
B, Xu L, Liang Y, Jamieson AC, Zhang L, Spratt SK, Case CC, 
95. Esteban-Barragan M, Avila P, Alvarez-Tejado M, Gutierrez M, 
Garcia-Pardo A, Sanchez-Madrid F, Landazuri M: Role of the 
von Hippel-Lindau tumor suppressor gene in the formation of 
96. Ananth S, Knebelmann B, Gruning W, Dhanabal M, Walz G, 
Stillman I, Sukhatme V: Transforming growth factor β1 is 
a target for the von Hippel-Lindau tumor suppressor and a critical 
growth factor for clear cell renal carcinoma. Cancer Res 59: 
2210–2216, 1999
97. Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, 
Kishida T, Kaneko S, Yao M, Ohno S, Shuin T: Direct interaction 
of the beta-domain of VHL tumor suppressor protein with the 
regulatory domain of atypical PKC isotypes. Biochem Biophys 
Res Commun 263: 491–497, 1999
N, Ohno S, Shuin T: The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein ki-
Sp1-mediated vascular permeability factor/vascular endothelial 
100. Pal S, Claffey K, Dvorak H, Mukhopadhyay D: The von 
Hippel-Lindau gene product inhibits vascular permeability factor/vascular 
endothelial growth factor expression in renal cell carcinoma 
by blocking protein kinase C pathways. J Biol Chem 272: 
27509–27512, 1997
padhyay D: Inhibition of insulin-like growth factor-I-mediated 
cell signaling by the von Hippel-Lindau gene product in renal 
102. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D: The 
104–123 amino acid sequence of the beta-domain of von 
Hippel-Lindau gene product is sufficient to inhibit renal tumor growth 
103. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner 
RD: VHL-mediated hypoxia regulation of cyclin D1 in renal 
104. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesner MS, 
Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER: 
Identification of cyclin D1 and other novel targets for the von 
Hippel-Lindau tumor suppressor gene by expression array anal-
ysis and investigation of cyclin D1 genotype as a modifier in the 
growth factor alpha is a target for the von Hippel-Lindau tumor 
106. Ramp U, Reinecke P, Gabbert H, Gerharz C: Differential re-
response to transforming growth factor (TGF)-α and fibroblast 
growth factor (FGF) in human renal cell carcinomas of the clear 
Marx N, Gabbert HE, Gerharz CD: Functional intactness of stimulatory and inhibitory autocrine loops in human renal carci-

Copyright © American Society of Nephrology. Unauthorized reproduction of this article is prohibited.
noma cell lines of the clear cell type. **J Urol** 157: 2345–2350, 1997


133. Nwogu JI, Gleen D, Bean M, Brenner MB, Huang X, Buttrick PM: Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilation after myocardial infarction. **Circulation** 104: 2216–2221, 2001